Nektar Therapeutics (NKTR): Insiders Aren't Crazy About It But Hedge Funds Love It
Now, according to many of your peers, hedge funds are assumed to be useless, outdated investment vehicles of a forgotten age.
Santarus Inc (SNTS)
This company is not actively trading or the ticker does belong to another company in our database now.
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Cheyne Capital Jonathan Lourie And Stuart Fiertz | 0 | $0 | 0% | |
| 2. | Water Island Capital John Orrico | 0 | $0 | 0% | |
| 3. | Springbok Capital Gavin Saitowitz And Cisco J. Del Valle | 0 | $0 | 0% | |
| 4. | Stevens Capital Management Matthew Tewksbury | 0 | $0 | 0% | |
| 5. | Marshall Wace LLP Paul Marshall And Ian Wace | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $10.88 | 185,000 | $2,012,800.00 | 335,500 | 2012-12-18 | Filing | |
| $5.34 | 2,000 | $10,674.60 | 18,000 | 2012-03-21 | Filing | |
| $5.35 | 4,000 | $21,380.00 | 16,000 | 2012-03-21 | Filing | |
| $5.34 | 1,000 | $5,340.00 | 12,000 | 2012-03-21 | Filing | |
| $5.34 | 2,000 | $10,675.60 | 11,000 | 2012-03-21 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $31.95 | 7,500 | $239,598.75 | 0 | 2013-12-16 | Filing | |
| $31.95 | 56,643 | $1,809,460.64 | 329,282 | 2013-12-16 | Filing | |
| $31.95 | 15,165 | $484,459.57 | 443 | 2013-12-09 | Filing | |
| $32.02 | 56,644 | $1,813,706.89 | 329,282 | 2013-11-15 | Filing | |
| $32.01 | 7,500 | $240,065.25 | 0 | 2013-11-15 | Filing |
News See All
Santarus, Inc. (SNTS), Nuance Communications Inc. (NUAN), Baidu.com, Inc. (ADR) (BIDU): Here's What This $17 Billion Money Manager Has Been Buying
Today, let's look at Fred Alger Management, founded in 1964, and managing mutual funds, pension funds, and more.
Santarus, Inc. (SNTS), Pharmacyclics, Inc. (PCYC), Ariad Pharmaceuticals, Inc. (ARIA): Should You Jump on This Biotech After Profit-Taking?
After a truly remarkable 20-month 650% gain, shares of Santarus, Inc. (NASDAQ:SNTS) have fallen by more than 20% since its all-time high in early August.
PDL BioPharma Inc. (PDLI): Hedge Fund and Insider Sentiment Unchanged, What Should You Do?
In the eyes of many market players, hedge funds are seen as overrated, old investment tools of a period lost to current times.
Santarus, Inc. (SNTS): Hedge Funds Are Bullish and Insiders Are Undecided, What Should You Do?
In the financial world, there are a multitude of gauges investors can use to watch publicly traded companies. A couple of the best are hedge fund and insider trading interest.
Hedge Funds Are Selling Sarepta Therapeutics Inc (SRPT)
If you were to ask many of your fellow readers, hedge funds are seen as overrated, old investment vehicles of a period lost to current times.
Santarus, Inc. (SNTS), Aegerion Pharmaceuticals, Inc. (AEGR), Ariad Pharmaceuticals, Inc. (ARIA): Did a Strong New Drug Make This Biotech Overvalued?
Santarus, Inc. (NASDAQ:SNTS) has risen over 300% in the past year partly based on sales optimism for ulcerative colitis drug Uceris, which launched in the first quarter.
What Hedge Funds Think About VIVUS, Inc. (VVUS)
In the 21st century investor’s toolkit, there are dozens of metrics investors can use to track Mr. Market. A couple of the most underrated are hedge fund and insider trading movement.
Regeneron Pharmaceuticals Inc (REGN), Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ): Have These 3 Biotechs Reached A Peak?
On Tuesday, several of biotechnology’s hottest names announced earnings. Despite strong results, the market appears to have grown accustomed to perfection.
Santarus, Inc. (SNTS), Jazz Pharmaceuticals plc - Ordinary Shares (JAZZ): Three Earning Catalysts That Could Push This Biotech Even Higher
Santarus, Inc. (NASDAQ:SNTS) has traded higher by 250% over the last year, and much of those gains have been created after the company’s last two quarterly reports.